Reports Search

A new World Health Organization (WHO) report highlights that 5.6 billion people – 71% of the world’s population – are now protected with at least one best practice policy to help save lives from deadly tobacco – five times more than in 2007.

In the last 15 years since WHO’s MPOWER tobacco control measures were introduced globally, smoking rates have fallen. Without this decline there would be an estimated 300 million more smokers in the world today.

This WHO Report on the global tobacco epidemic, supported by Bloomberg Philanthropies, is focused on protecting the public from second-hand smoke, highlighting that almost 40% of countries now have completely smoke-free indoor public places.

The report rates country progress in tobacco control and shows that two more countries, Mauritius and the Netherlands, have achieved best-practice level in all MPOWER measures, a feat that only Brazil and Türkiye had accomplished until now.

Notable progress has been made since May 2023 by the Intergovernmental Negotiating Body to draft and negotiate a WHO convention, agreement or other international instrument on pandemic prevention, preparedness and response (the INB). The Seventy-sixth World Health Assembly in May 2023 played an important role in maintaining the momentum towards our objective to deliver a pandemic accord to the World Health Assembly (WHA) in May 2024. Shortly after, on 12-16 June 2023, the INB Bureau continued its work during the resumed session of the fifth meeting of the INB (INB5 resumed session). The INB considered the Bureau’s text and agreed on innovative ways of working, empowering interested Member States to facilitate informal discussions. We are grateful for the leadership of the WHO Member States that have volunteered to help to bridge the gaps on key issues. Their hard work during the intersessional period will pay off. Once again, our diversity will make us stronger.

WHO member states came together in recent days in the first substantive joint session that brought together the bureaux of the Intergovernmental Negotiating Body and the Working Group of amendments to the International Health Regulations.

With a mere ten months away from the May 2024 deadline, where both these processes are expected to conclude and culminate in the adoption of new amendments to the IHR and a potentially new pandemic instrument, countries this week grappled with the basics such as what would legally constitute a pandemic, how it would be declared, what kind of actions would it trigger and most importantly, how would these elements sit across the two different, overlapping legal mechanisms. There was also consideration of a few key topics that have featured in both these tracks of negotiations.

… Overlooking the inclusion of Africa CDC, which is the sole continental public health institution, was an unfortunate oversight. As a result, Africa’s health security gaps remain inadequately addressed, leading to the absence of multi-country/regional proposals from the continent. Africa CDC would like to recall that in February 2023, it reiterated its stance as an observer at the Pandemic Fund’s Board, emphasizing the significance of inclusive representation in the Fund’s governance structures, technical teams, and Secretariat to inform its crucial work. Africa CDC would also like to echo the call from African Heads of State and Government for a better representation of Africa in all multilateral constituencies. Africa CDC further urges for equitable representation of African countries and regional organizations in the relevant structures to ensure fair and inclusive outcomes. Therefore, Africa CDC once again urges the Pandemic Fund to take decisive action for the admission of Africa CDC as an Implementing Entity to join the ones identified in 2022.

India has long been known as the “pharmacy of the world,” producing generic medicines at prices that other developing countries and global institutions can afford. The country was the single largest supplier of pharmaceutical products to Africa in 2018, and accounted for a fifth of the continent’s pharmaceutical imports.

However, as the European Union now negotiates free trade agreements with India and Indonesia — another major generics-producing nation — the bloc’s been proposing far stricter protection of intellectual property rights. And such protection could threaten the affordability of generic medicines these countries export to the Global South.

It’s vital we remember the lessons of the HIV and AIDS pandemic. 

The thorny and unresolved issues of how to incorporate health equity measures and supportive finance for low and middle income countries into revisions of the WHO International Health Regulations (IHR), are set to be two key items on the agenda of an IHR negotiating body when talks resume again in early October. 

This was one of the key messages at the close of the fourth meeting of the WHO Working Group on Amendments to the International Health Regulations, which concluded today after a week of discussions. 

Although most negotiations took place behind closed doors, the meeting report that was discussed briefly in a public session on Friday provided a snippet of the talks so far and the envisioned way forward.  

In the politically charged discussions that current global health negotiations have become, diplomats have to walk a tightrope between delivering on political goals and bringing in concrete reforms to beef up preparedness, prevention and respond to health emergencies. The relative low profile of the discussions surrounding the amendments to the IHR (2005) is in contrast to the optics generated by the negotiations for a Pandemic Accord. This could be partly by design, and partly by the very nature of these discussions that are technical but undoubtedly also political. During the sidelines of the WG-IHR4, Geneva Health Files, spoke with Abdullah Asiri and Ashley Bloomfield, Co-Chairs of the WG-IHR talk about how they see these negotiations progressing. Countries have often described this track fo global helathnegotiations as being efficient and streamlined.

The thorny and unresolved issues of how to incorporate health equity measures and supportive finance for low and middle income countries into revisions of the WHO International Health Regulations (IHR), are set to be two key items on the agenda of an IHR negotiating body when talks resume again in early October. 

This was one of the key messages at the close of the fourth meeting of the WHO Working Group on Amendments to the International Health Regulations, which concluded today after a week of discussions. 

… According to global health charity Medicins Sans Frontieres (MSF), J&J currently prices the drug at USD1.50/day for an adult treatment (USD272/six months). But with scale-up and unrestricted generic competition, it says the price of bedaquiline could get closer to USD0.50 per day. … But even if the deal does bring the price down to that level, some of the countries which would benefit from purchasing the drug at a lower price will not be able to as they have been excluded from it. Nine countries in the Eastern European and Central Asian region, which have some of the highest TB burdens in the world, are not covered by the deal because of an exclusive supply agreement J&J has with a Russian pharma firm. … The exclusion has infuriated senior health officials in some of the excluded countries. In a rare instance of its kind, the national tuberculosis (TB) programme (NTP) of Belarus sent an open letter to J&J demanding urgent action to improve equitable access to bedaquiline in Belarus, and all other countries with a high burden of TB.

The fourth meeting of the Working Group on Amendments to the International Health Regulations (WGIHR4) is to discuss various developed country amendment proposals focusing on accelerated information sharing and compliance. These proposals are from the USA, the European Union (EU), Switzerland and New Zealand. WGIHR4 will take place at the WHO Headquarters in Geneva on 24-28 July in a hybrid mode. … The third meeting of WGIHR had focussed on amendment proposals on Article 13 (public health response), new article 13 A (equitable access to health products, technologies and know-how), 43 (additional health measures), 44 (collaboration and cooperation), new article 44A (financing mechanism), New Article 53A (implementation and compliance). This week the majority of the amendment proposals under consideration are from developed countries. Many of these aim at enhancing the obligations on information sharing and compliance that on the surface seem reasonable but can be negative for developing countries.